Cannabinoids, such as cannabidivarin (CBDV) may be rare, but may also have exciting potential. Indeed, according to InMed Pharmaceuticals Inc. (NASDAQ:INM), “CBDV is one of the most studied rare cannabinoids and has been researched in autism, epilepsy, acne, alopecia, inflammatory diseases of the bowel, nausea and pain. CBDV is also currently being studied in a number of clinical trials, including in autism, Prader-Willi syndrome, and attention deficit hyperactivity disorder (ADHD). Additionally, as Rare Cannabinoid Company notes, “CBDV is a strain. Varines contain two carbon atoms less than their non-varines counterparts (THC and CBD). These differences mean that they interact with the human endocannabinoid system in different ways and have unique physiological effects. In short, the future may be bright for companies, like InMed Pharmaceuticals, which has just announced that it has launched B2B sales of the rare cannabinoid cannabidivarin to wholesalers, suppliers and manufacturers of finished products in the healthcare sector and wellness through its US subsidiary, BayMedica LLC. . Other related companies to know include Tilray Inc. (NASDAQ:TLRY), canopy growth (TSX: WEED) (NASDAQ: CGC), Jazz Pharmaceutical (NASDAQ: JAZZ), and AbbVie Inc. (NYSE: ABBV).
InMed Pharmaceuticals Inc. (NASDAQ: INM) has just launched B2B sales of Cannabidivarin
InMed Pharmaceuticals Inc., a leader in the research, development, manufacturing and marketing of rare cannabinoids, is pleased to announce that it has launched B2B sales of the rare cannabinoid cannabidivarin to wholesalers, suppliers and product manufacturers. finished in the health and wellness sector through its US subsidiary, BayMedica LLC.
“Ensuring a reliable, high-volume source of highly pure, bio-identical CBDV is a significant step forward in the health and wellness industry. CBDV has been researched for its therapeutic potential in several disease areas such as autism spectrum disorders,” said Shane Johnson, MD, SVP and Chief Executive Officer of BayMedica. “Whether you are a researcher or a product developer at a multinational consumer goods company, the ability to access highly pure and consistent active ingredients free of contaminants typically found in plant-derived cannabinoids such as pesticides, metals heavy or potentially even THC, is a fundamental requirement. BayMedica’s cannabinoid manufacturing technologies offer exactly that value and we are excited to continue to bring additional rare cannabinoids to the market that were previously not accessible in abundance, including including adding THCV to our portfolio in the immediate future.
CBDV – An Important Twist on CBD
CBDV is a rare, non-intoxicating cannabinoid that has a similar molecular structure to CBD but with two fewer carbon atoms on its side chain, resulting in significant differences in potency. The BayMedica team has curated a collection of scientific research studies on the physiological and potential therapeutic properties of CBDV. CBDV is one of the most studied rare cannabinoids and has been researched for autism, epilepsy, acne, alopecia, inflammatory bowel disease, nausea and pain . CBDV is also currently being studied in a number of clinical trials, including in autism, Prader-Willi syndrome, and attention deficit hyperactivity disorder (ADHD).
Click here to download the white paper.
BayMedica – We use cannabinoids differently
BayMedica manufactures rare cannabinoids through novel synthetic methods that ensure reproducible quality and purity. The Company’s products are manufactured under GMP (Good Manufacturing Practices) food grade standards for the health and wellness industry, and are bio-identical to plant-derived compounds. These cannabinoids can be custom formulated for a variety of consumer health and wellness applications, including supplements, nutraceuticals, cosmetics, and animal health. Using repeatable processes ensures the purity and consistency of our cannabinoids every time. Additionally, these production methods can be scaled up to meet demand to ensure customers have a continuous source of cannabinoids without supply chain issues.
Increase in demand for rare cannabinoids
As research continues to identify the unique characteristics of cannabinoids beyond THC and CBD, the use and acceptance of all cannaboinds is poised to grow significantly over the months and years to come. to come. Key metrics that point to significant growth include online analytics, emerging trends in the regulated hemp and marijuana sectors, and R&D among multinational CPGs. Reports such as the December 2021 Grand View Research report, which predicts that the retail market for rare cannabinoids will reach US$26 billion by 2028, add to the growing body of data.
By establishing a reliable supply of these rare cannabinoids on a commercial scale, innovative product manufacturers and consumer brands now have the ability to offer enhanced and differentiated products through product line extensions and formulations designed to increase performance of their products.
For more information on purchasing CBDV and other rare cannabinoids, please contact the BayMedica sales team at: [email protected]
Learn more about BayMedica’s products:
Minor cannabinoids CBC CBDV THCV CBT | BayMedica
Other related market developments include:
Tilray Inc. announced its financial results for the third fiscal quarter. Irwin D. Simon, Chairman and CEO of Tilray, said, “Our third quarter results reflect progress and momentum across all of our key businesses and geographies, setting the stage for reaching our $4 billion target. dollars in revenue by the end of the fiscal year. 2024. Tilray Medical – now operating under a cohesive strategy and mission – has a nearly 20% market share in Germany, offering clear full-fledged advantages as well as a first-mover advantage which we will leverage as Germany and the EU move towards broader legalization of adult and medical use. In Canada, we maintained our market share leadership position in an environment of intense competition – and we believe that our strong capital position, operational excellence and pricing and marketing adjustments will work together to help us recover market share over the next few quarters.
canopy growth, a diversified cannabis, hemp and cannabis-based device company in the world, unveils its 7ACRES Know the Grow content series, giving Canadians insight into the talent, genetics and cultivation techniques behind the brand and flower wallet. The ten-video series is divided into three chapters: 7ACRES Kincardine Facility, Growing Techniques and 7ACRES Craft Collective + Future Vision, with each episode delving into a different element of production. The series launched in mid-February and releases a new episode every week via the 7ACRES.com blog, The Stash, as well as the 7ACRES Instagram channel, @7acresmj.
Jazz Pharmaceutical announced that it will release its first quarter 2022 financial results on Wednesday, May 4, 2022, after U.S. financial markets close. Company management will host a live audio webcast at 4:30 p.m. ET / 9:30 p.m. IST to discuss the first quarter 2022 financial results and provide a business and financial update.
AbbVie Inc. will announce its first quarter 2022 financial results on Friday, April 29, 2022, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. CT. It will be accessible through AbbVie’s Investor Relations website, Investors.abbvie.com. An archived edition of the session will be available later today.
Disclaimer / Except for historical information presented herein, the matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied. -understood by these statements. Winning Media is not registered with any financial or securities regulatory authority and does not provide or purport to provide investment advice or recommendations to readers of this release. To make specific investment decisions, readers should seek their own advice. InMed Pharmaceuticals Inc. paid three thousand five hundred dollars for advertising and marketing services to be distributed by Winning Media. Winning Media is only compensated for its services in the form of cash compensation. Winning Media owns NO shares of InMed Pharmaceuticals Inc. Click here for disclaimer.